"The Doctor Says You Cannot Have [Buprenorphine]" Autonomy and Use of Prescribed or Non-Prescribed Buprenorphine.

"The Doctor Says You Cannot Have [Buprenorphine]" Autonomy and Use of Prescribed or Non-Prescribed Buprenorphine.
复制标题

DOI:
10.1080/10826084.2021.1908360
复制
发表时间:
2021
影响因子:
2
通讯作者:
Fox AD
Fox AD
中科院分区:
医学4区
文献类型:
--
作者:
Hayes BT;Jakubowski A;Fitzsimmons C;Garcia B;Ramirez F;Fox AD

文献摘要

参考文献

被引文献

相似文献

People may overcome barriers to professional buprenorphine treatment by using non-prescribed buprenorphine (NPB) to manage opioid use disorder (OUD). Little is known about how people perceive NPB differently than formal treatment. This qualitative study investigated how and why people use NPB as an alternative to formal treatment. In-depth, semi-structured interviews were conducted with participants of harm reduction agencies (N = 22) who had used buprenorphine. Investigators independently coded transcribed interviews, generating themes through iterative reading and analysis of transcripts. Three main factors drove decisions about prescribed and non-prescribed buprenorphine use: 1) autonomy; 2) treatment goals; and 3) negative early experiences with NPB. An overarching theme from our analysis was that participants valued autonomy in seeking to control their substance use. NPB was a valuable tool towards this goal and professional OUD treatment could impede autonomy. Participants mostly used NPB to “self-manage” OUD symptoms. Many participants had concerns about long-term buprenorphine treatment and instead used NPB over short periods of time. Several participants also reported negative experiences with NPB, including symptoms of withdrawal, which then deterred them from seeking out professional treatment. These results support prior studies showing that people use NPB to self-manage withdrawal symptoms and to reduce use of illicit opioids. Despite these benefits, participants focused on short-term goals and negative consequences were common. Increasing buprenorphine treatment engagement may require attention to patients’ sense of autonomy, and also assurance that long-term treatment is safe, effective, and reliably accessible.
DOI: 10.1097/adm.0000000000000436
发表时间: 2018-11-01
影响因子: 5.5
作者:
Carroll, Jennifer J.;Rich, Josiah D.;Green, Traci C.
通讯作者: Green, Traci C.
DOI: 10.1097/adm.0000000000000045
发表时间: 2014-09
影响因子: 5.5
作者:
Lofwall MR;Walsh SL
通讯作者: Walsh SL
DOI: 10.1097/adm.0b013e31829727b2
发表时间: 2013-07
影响因子: 5.5
作者:
Cunningham CO;Roose RJ;Starrels JL;Giovanniello A;Sohler NL
通讯作者: Sohler NL
DOI: 10.3109/10826084.2010.501655
发表时间: 2011-01-01
影响因子: 2
作者:
Dean, Angela J.;Saunders, John B.;Bell, James
通讯作者: Bell, James
DOI: 10.1186/s13011-016-0085-y
发表时间: 2017-01-11
期刊: Substance abuse treatment, prevention, and policy
影响因子: --
作者:
Hewell VM;Vasquez AR;Rivkin ID
通讯作者: Rivkin ID